Literature DB >> 11122927

Current and future treatments for cognitive deficits in dementia.

B M McLendon1, G G Chen, P M Doraiswamy.   

Abstract

In this article, we primarily focus on the treatment approaches currently marketed and in advanced stages of development for Alzheimer's disease (AD). Amyloid plaques and neurofibrillary tangles remain the pathologic hallmarks of AD, and much progress has been made in unraveling the molecular biology of these changes. In addition, there is also intense research into inflammatory and oxidative mechanisms as well as vascular and neurochemical alterations in AD. Therapies targeted at these mechanisms are discussed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11122927     DOI： 10.1007/s11920-000-0037-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  10 in total

Review 1.  Defining meaningful change in Alzheimer's disease trials: the donepezil experience.

Authors:  B M McLendon; P M Doraiswamy
Journal:  J Geriatr Psychiatry Neurol       Date:  1999       Impact factor: 2.680

2.  Searching for drugs that combat Alzheimer's.

Authors:  J Marx
Journal:  Science       Date:  1996-07-05       Impact factor: 47.728

3.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

4.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

Authors:  M X Tang; D Jacobs; Y Stern; K Marder; P Schofield; B Gurland; H Andrews; R Mayeux
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

5.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

6.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06

Review 7.  The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.

Authors:  B S Oken; D M Storzbach; J A Kaye
Journal:  Arch Neurol       Date:  1998-11

Review 8.  Current status of antioxidant therapy for Alzheimer's Disease.

Authors:  S S Pitchumoni; P M Doraiswamy
Journal:  J Am Geriatr Soc       Date:  1998-12       Impact factor: 5.562

9.  Clinical trial of indomethacin in Alzheimer's disease.

Authors:  J Rogers; L C Kirby; S R Hempelman; D L Berry; P L McGeer; A W Kaszniak; J Zalinski; M Cofield; L Mansukhani; P Willson
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

10.  Combination therapy for early Alzheimer's disease: what are we waiting for?

Authors:  P M Doraiswamy; D C Steffens
Journal:  J Am Geriatr Soc       Date:  1998-10       Impact factor: 5.562
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.